Heat Biologics Inc. [NASDAQ: HTBX] loss -9.65% or -0.11 points to close at $1.03 with a heavy trading volume of 8254894 shares. The company report on November 9, 2020 that Heat Biologics Provides Third Quarter 2020 Business Update.
Continued progress on oncology and COVID-19 vaccine programs.
Over $117 million of cash and short-term investments .
It opened the trading session at $1.11, the shares rose to $1.12 and dropped to $1.01, the range by which the price of stock traded the whole day. The daily chart for HTBX points out that the company has recorded 75.47% gains over the past six months. However, it is still -442.11% lower than its most recent low trading price.
If we look at the average trading volume of 11.04M shares, HTBX reached to a volume of 8254894 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Heat Biologics Inc. [HTBX]:
B. Riley Securities have made an estimate for Heat Biologics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 14, 2020. The new note on the price target was released on June 20, 2016, representing the official price target for Heat Biologics Inc. stock. Previously, the target price had yet another raise to $16, while Noble Financial analysts kept a Buy rating on HTBX stock.
The Average True Range (ATR) for Heat Biologics Inc. is set at 0.08, with the Price to Sales ratio for HTBX stock in the period of the last 12 months amounting to 44.87. The Price to Book ratio for the last quarter was 1.91, with the Price to Cash per share for the same quarter was set at 0.31.
Trading performance analysis for HTBX stock
Heat Biologics Inc. [HTBX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.45. With this latest performance, HTBX shares dropped by -17.60% in over the last four-week period, additionally plugging by 75.47% over the last 6 months – not to mention a rise of 110.20% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HTBX stock in for the last two-week period is set at 34.62, with the RSI for the last a single of trading hit 24.33, and the three-weeks RSI is set at 38.00 for Heat Biologics Inc. [HTBX]. The present Moving Average for the last 50 days of trading for this stock 1.2219, while it was recorded at 1.1380 for the last single week of trading, and 0.9952 for the last 200 days.
Heat Biologics Inc. [HTBX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Heat Biologics Inc. [HTBX] shares currently have an operating margin of -636.11. Heat Biologics Inc.’s Net Margin is presently recorded at -656.51.
Return on Total Capital for HTBX is now -85.58, given the latest momentum, and Return on Invested Capital for the company is -87.94. Return on Equity for this stock declined to -91.28, with Return on Assets sitting at -34.96. When it comes to the capital structure of this company, Heat Biologics Inc. [HTBX] has a Total Debt to Total Equity ratio set at 14.21. Additionally, HTBX Total Debt to Total Capital is recorded at 12.44, with Total Debt to Total Assets ending up at 3.58. Long-Term Debt to Equity for the company is recorded at 12.25, with the Long-Term Debt to Total Capital now at 10.72.
Reflecting on the efficiency of the workforce at the company, Heat Biologics Inc. [HTBX] managed to generate an average of -$556,044 per employee. Receivables Turnover for the company is 96.00 with a Total Asset Turnover recorded at a value of 0.05.Heat Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.70 and a Current Ratio set at 7.70.
Heat Biologics Inc. [HTBX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Heat Biologics Inc. posted -0.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.14/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 28.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HTBX.
An analysis of insider ownership at Heat Biologics Inc. [HTBX]
There are presently around $10 million, or 12.10% of HTBX stock, in the hands of institutional investors. The top three institutional holders of HTBX stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 3,032,074, which is approximately 68.581% of the company’s market cap and around 3.23% of the total institutional ownership; BLACKROCK INC., holding 2,406,112 shares of the stock with an approximate value of $2.48 million in HTBX stocks shares; and VANGUARD GROUP INC, currently with $2.31 million in HTBX stock with ownership of nearly 6.705% of the company’s market capitalization.
Positions in Heat Biologics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 28 institutional holders increased their position in Heat Biologics Inc. [NASDAQ:HTBX] by around 3,254,035 shares. Additionally, 9 investors decreased positions by around 3,938,031 shares, while 0 investors held positions by with 2,179,621 shares. The mentioned changes placed institutional holdings at 9,371,687 shares, according to the latest SEC report filing. HTBX stock had 18 new institutional investments in for a total of 623,308 shares, while 6 institutional investors sold positions of 185,620 shares during the same period.